Erratum to: Recombinant viral protein VP1 suppresses HER-2 expression and migration/metastasis of breast cancer

Erratum to: Breast Cancer Res Treat DOI 10.1007/s10549-012-2238-7

Unfortunately, in the original publication of the article, there were several errors in Figs. 1a, 2c, and 5c. The authors apologize for these errors. The corrected Figs. 1a, 2c, and 5c are given below.

Fig. 1

rVP1 induces cell morphological alteration and mesenchymal-to-epithelial transition in breast cancer cells. a After rVP1 treatment at 37 °C for 24 h, cell morphology was observed by light microscopy. rVP1-induced alteration of cell morphology from the spindle shape to a round or cuboid shape in TS/A and MDA-MB-231 (231) cells. Bar 5 μm. b Fluorescence staining showed an increase in expression of E-cadherin (E-Cad) and a decrease in expression of α-vimentin (Vim) in rVP1-treated TS/A or MDA-MB-231 cells. c The E-Cad⁺ populations of rVP1-treated TS/A and MDA-MB-231 cells increased, but the Vim cell populations decreased. The presence of E-Cad and Vim cells were determined by flow cytometry and the results were reproduced in three independent experiments. Data represent mean ± SD (n = 3) and ** P < 0.01. d The protein expressions of E-Cad and Vim were detected by Western blot. β-actin was used as a loading control

Fig. 2

rVP1 treatment suppresses HER-2 expression, migration/invasion, and metastasis of breast cancer in vitro and in vivo. a Protein and mRNA expression of HER-2 in the same four breast cancer cell lines after rVP1 treatment at 37 °C for 24 h in serum-free medium. Actin was used as a loading control. b Cell migration/invasion of breast cancer cells after rVP1 treatment at 37 °C for 24 h using Transwell migration assay. The results were reproduced in three independent experiments. Data represent mean ± SD (n = 3). *P < 0.05; **P < 0.01. c rVP1-pretreated breast cancer cells implanted intravenously via the tail vein. All mice (n = 4/group) were sacrificed at day 14 after inoculation. Gross and histopathologic appearances of lung and lung weight and the number of tumor foci in lung showed that rVP1 treatment suppressed metastasis of breast cancer cells to the lung in the classic experimental metastasis models. Data represent mean ± SD (n = 4). *P < 0.05; **P < 0.01; ***P < 0.001. White scale bar 1 cm; black scale bar 5 μm

Fig. 5

rVP1 treatment suppresses breast cancer metastasis in a murine orthotopic TS/A breast cancer allograft model. a The diagram depicts the timeline for orthotopic implantation of TS/A breast cancer cells, and the rVP1-therapy strategy: 1 or 25 mg/kg BW rVP1 by iv injection, three times/week for 4 weeks. The therapeutic periods were: early therapy (D1–D30), and late therapy (D31–D60). Three mice per group (n = 12/group) were sacrificed at the end point of each therapeutic period. The survival of the remaining mice was monitored. b Early therapy: gross appearance and the weight of orthotopic tumor mass were evaluated after 1 or 25 mg/kg BW rVP1 treatment. Data represent mean ± SD (n = 3). **P < 0.01 (vehicle group vs. rVP1-treated group). c Early therapy: gross and histopathologic appearances of lung and lung weight and the number of tumor foci in lung showed that rVP1 treatment suppressed metastasis of breast cancer cells to the lung. Arrows show tumor foci in lung. Data represent mean ± SD (n = 3). *P < 0.05; ***P < 0.001 (vehicle group vs. rVP1-treated group). "N" represents normal status of mice. "V" represents tumor implantation without rVP1 treatment. d Late therapy: the gross appearance and weight of orthotopic tumor mass was evaluated after 1 or 25 mg/kg BW rVP1 treatment. Data represent mean ± SD (n = 3). **P < 0.01 (vehicle group vs. rVP1—treated group). e Late therapy: the gross and histopathologic appearances of lung were evaluated after rVP1 treatment. Gross and histopathologic appearances of lung and lung weight and the number of tumor foci in lung showed that rVP1 treatment suppressed metastasis of breast cancer cells to the lung. Arrows show tumor foci in lung. Data represent means ± SD (n = 3). ***P < 0.001 (vehicle group vs. rVP1-treated group). f The survival of tumor-bearing mice was monitored after "early" and "late" rVP1 therapy (n = 9). **P < 0.01; ***P < 0.001. The experiment was performed twice and data are from one representative experiment